Mitsubishi UFJ Trust & Banking Corp Sells 40,224 Shares of Kenvue Inc. (NYSE:KVUE)

Mitsubishi UFJ Trust & Banking Corp lowered its holdings in Kenvue Inc. (NYSE:KVUE) by 4.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 922,018 shares of the company’s stock after selling 40,224 shares during the period. Mitsubishi UFJ Trust & Banking Corp’s holdings in Kenvue were worth $19,685,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Meiji Yasuda Asset Management Co Ltd. raised its stake in Kenvue by 3.2% in the fourth quarter. Meiji Yasuda Asset Management Co Ltd. now owns 65,376 shares of the company’s stock valued at $1,396,000 after purchasing an additional 2,041 shares in the last quarter. Zions Bancorporation N.A. raised its position in shares of Kenvue by 13.2% during the 4th quarter. Zions Bancorporation N.A. now owns 223,555 shares of the company’s stock valued at $4,773,000 after buying an additional 26,026 shares in the last quarter. Corebridge Financial Inc. raised its position in shares of Kenvue by 4.2% during the 4th quarter. Corebridge Financial Inc. now owns 525,602 shares of the company’s stock valued at $11,222,000 after buying an additional 21,209 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Kenvue by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 218,543,705 shares of the company’s stock worth $4,665,908,000 after acquiring an additional 1,636,741 shares during the last quarter. Finally, LPL Financial LLC grew its position in Kenvue by 4.9% in the fourth quarter. LPL Financial LLC now owns 2,064,405 shares of the company’s stock worth $44,075,000 after acquiring an additional 96,030 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

Kenvue stock opened at $23.52 on Friday. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The firm has a market cap of $44.95 billion, a P/E ratio of 44.38, a P/E/G ratio of 2.62 and a beta of 1.25. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46. The firm has a 50-day moving average of $22.27 and a 200-day moving average of $22.46.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Sell-side analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were given a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 3.49%. The ex-dividend date was Wednesday, February 12th. Kenvue’s payout ratio is currently 154.72%.

Wall Street Analyst Weigh In

KVUE has been the subject of a number of research reports. Canaccord Genuity Group upped their price objective on Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a report on Wednesday, March 5th. Barclays upped their target price on Kenvue from $21.00 to $23.00 and gave the stock an “equal weight” rating in a research note on Thursday. UBS Group decreased their price target on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research note on Friday, February 7th. Piper Sandler upped their price objective on shares of Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a research note on Monday, February 24th. Finally, Evercore ISI initiated coverage on shares of Kenvue in a research report on Monday. They issued an “in-line” rating and a $25.00 target price on the stock. One analyst has rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $24.00.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.